IPS Therapeutique is a specialty Contract Research Organization which dedicates its expertise and technology to the evaluation of the cardiac safety of new drugs at an early stage of their development, by using validated and highly predictive models. Recognized for the quality and the on-time delivery of its IND enabling studies, IPS Therapeutique addresses the particular needs of start-up and mature biopharmaceutical companies which are looking for fast and cost-effective solutions to assess the QT Prolongation and the arrhythmogenic liability of their new compound(s) during preclinical development
GLP-Compliant, AALAC accredited
Methodologies: Manual Patch clamp (screens and GLP-compliant) of various native or transfected ionic currents Langendorff (isolated heart) constant pressure or flow, ECG monitoring, Left ventricular pressure (LVP), perfusion pressure, coronary flow, and sinus or paced rhythm. ECG and blood pressure monitoring on anaesthetized animals Organs perfusion Isolated cardiomyocytes Isolated ventricular trabeculae mounted in vertical organ bath with electric field stimulation Action potential kinetics analysis (Purkinje repolarisation assay) with high-resistance micro-electrode impalement